Nanocarrier-mediated co-delivery systems for lung cancer therapy: recent developments and prospects

Abstract

Research has recently focused on combinational therapy using nanocarriers to overcome the obstacles associated with conventional therapy of lung cancer. The classical therapeutic approach is indeed insufficient for suppressing tumor growth. Simultaneous delivery improves therapeutic outcomes, synergistic effects, and targeting moiety. Besides, multidrug-loaded nanocarriers allows the consecutive release of two or more drugs and genes. A such nanodrug delivery system reduces drug–drug interactions and improves the pharmacokinetics profile of loaded drugs. Currently, nanotechnology-based co-delivery system is the only suitable option for lung cancer therapy. Combinational delivery systems show promising results for the treatment of lung cancer. Here we review the design and development of co-delivery systems based on nanocarriers for effective cancer treatment.